In view of the most recent changes in advice/restrictions to the general population, the board of the Belgian Study Group of MS (BSGMS) strengthens its advice to neurologists regarding the treatment of MS patients. Therefore, following recommendations apply: 1. The preventive measures provided to the general population (https://www.info-coronavirus.be/nl/ or https://www.info-coronavirus.be/fr/) do apply even more to…
Détails
In line with its mission to support the treatment of MS, the Belgian Study Group for MS (BSGMS) would like to provide you with a response to some frequently asked questions regarding the current coronavirus issue. Most importantly we adhere to the guidelines of our health authorities: https://www.info-coronavirus.be/nl/ or https://www.info-coronavirus.be/fr/, which are updated when necessary.…
DétailsThe organisation’s non-profit purpose is to encourage and develop in Belgium, in cooperation with the Belgian Charcot Foundation – the foundation of public interest which it created – the study and treatment of multiple sclerosis, by means of the various scientific-research disciplines available, in particular clinical research, biology, biochemistry, electrophysiology, immunology, virology, genetics, epidemiology and anatomopathology.
Chairman: Prof Bénédicte Dubois
Vice-president: Prof Guy Laureys
Secretary: Dr Dominique Dive
Members: Dr Melissa Cambron, Dr Brigitte Capron, Dr Bernard Dachy, Dr Danny Decoo, Prof Soraya El Sankari, Dr Frederic London, Dr Gaetano Perrotta, Prof. Veronica Popescu, Prof Vincent van Pesch, Prof Bart Van Wijmeersch, Dr Barbara Willekens
Executive officer : Mrs Isabelle Bloem-Gonsette
BELTRIMS (Belgian Treatment in Multiple Sclerosis) :
Le but de ce registre est de collecter des données, en situation réelle, sur la tolérance et l’efficacité des nouveaux médicaments, de détecter à court et long terme des effets secondaires inconnus ou sous-évalués et d’étudier les effets éventuels des médicaments concernés en cas de grossesse.
Het doel van het register is het verzamelen van real life data over de tolerantie en de werkzaamheid van de nieuwe behandelingen, om zo op korte en lange termijn nog niet ontdekte bijwerkingen in het licht te stellen en de eventuele effecten op zwangerschap te bestuderen.